Latus Bio to Spotlight Advances in Gene Therapy at ASGCT Annual Meeting
PHILADELPHIA, PA — Latus Bio Inc. (Latus) will showcase its groundbreaking progress in AAV capsid variants—AAV-DB-3 and AAV-Ep+—at the 2025 American Society for Gene and Cell Therapy (ASGCT) Annual Meeting …
Latus Bio to Spotlight Advances in Gene Therapy at ASGCT Annual Meeting Read More